Table 1 Main patient characteristics
From: A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Characteristics | Number of patients (%) |
|---|---|
Median age (59 years) | Â |
  -Age between 18–59 years | 55 (51) |
  -Age > 59 years | 53 (49) |
Performance status (PS Ecog) | Â |
  -0 | 80 (74) |
  -1 | 25 (23) |
  -2 | 3 (3) |
Stage at diagnosis (n) | Â |
  -Stage I | 22 (20) |
  -Stage II | 6 (5) |
  -Stage III | 49 (45) |
  -Stage IV | 31 (29) |
Grading | Â |
  -G1 | 11 (10) |
  -G2 | 26 (24) |
  -G3 | 71 (66) |
Median value of CA 125 | Â |
  CA 125 ≥ 205 | 46 (42) |
  Ca 125 < 205 | 43 (40) |
D-dimer | Â |
  -Hig D-dimer value | 17 (16) |
  -Low D-dimer value | 15 (14) |
Comorbidity | Â |
  -No comorbidity | 31 (29) |
  -Grade 1 comorbity | 10 (9) |
  -Grade 2 Comorbidity | 67 62) |
Adjuvant treatment | Â |
  -yes | 17 (16) |
  -no | 10 (9) |
First line treatment | Â |
  -yes | 64 (59) |
  -no | 2 (2) |
Neoadjuvant treatment | 15 (14) |